Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Myocarditis I: Introduction01:21

Myocarditis I: Introduction

Myocarditis is inflammation of the myocardium, which is the muscular layer of the heart.EtiologyMyocarditis has a diverse etiology, including a wide range of infectious and non-infectious causes:Infectious CausesViral: Common viruses include Coxsackie A and B, adenovirus, parvovirus B19, enteroviruses, and influenza A.Bacterial: Examples include infections caused by Streptococcus, Staphylococcus, and Mycoplasma species.Rickettsial: Infections like Rocky Mountain spotted fever can result in...
Cardiomyopathy I: Introduction and Classification01:25

Cardiomyopathy I: Introduction and Classification

Cardiomyopathy, or CMP, is a group of diseases affecting the myocardial structure, impairing its ability to pump blood effectively. This condition can lead to arrhythmias, heart failure, or sudden cardiac death.Cardiomyopathies are classified into primary and secondary categories:Primary Cardiomyopathy refers to conditions involving only the heart muscle that are often idiopathic (of unknown cause) or genetic. They primarily affect the myocardium without the involvement of other systemic...
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
Cardiomyopathy IV: Restrictive Cardiomyopathy01:29

Cardiomyopathy IV: Restrictive Cardiomyopathy

Restrictive cardiomyopathy (RCM) is a rare heart muscle disease characterized by impaired ventricular filling due to stiffened ventricular walls, leading to significant diastolic dysfunction.EtiologyRestrictive cardiomyopathy can arise from both inherited and acquired diseases, many of which are systemic. It is categorized into four main types: infiltrative, storage, non-infiltrative, and endomyocardial diseases.Infiltrative diseases, such as amyloidosis, lead to RCM by depositing amyloid...
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Therapeutic angiogenesis: time for the next phase.

Journal of the American College of Cardiology·2000
Same author

Abnormal adaptations to stress and impaired cardiovascular function in mice lacking corticotropin-releasing hormone receptor-2.

Nature genetics·2000
Same author

Counseling families with chromosome 22q11 deletions: the catch in CATCH-22.

Journal of the American College of Cardiology·1998
Same author

Phase II, placebo-controlled trial of MRX115 (Aerosomes) for left heart and myocardial perfusion imaging.

Academic radiology·1998
Same author

Ultrasound-mediated destruction of contrast agents. Effect of ultrasound intensity, exposure, and frequency.

Investigative radiology·1997
Same author

Therapeutic angiogenesis: just the basic fact(or)s, please.

Journal of the American College of Cardiology·1997
Same journal

Beyond therapeutic maximalism: Prioritization and personalization in preventive therapies.

Progress in cardiovascular diseases·2026
Same journal

Multimodality imaging of vulnerable plaque: Are we there yet? A multifaceted perspective.

Progress in cardiovascular diseases·2026
Same journal

Beyond LDL-C: Triangulating residual risk via lipoprotein(a), remnant cholesterol, and vascular inflammation.

Progress in cardiovascular diseases·2026
Same journal

COVID-19 and coronary atherosclerosis: Unmasking and accelerating?

Progress in cardiovascular diseases·2026
Same journal

Mavacamten and left ventricular dysfunction in hypertrophic cardiomyopathy with left bundle branch block.

Progress in cardiovascular diseases·2026
Same journal

Lessons from ATTR-CM clinical trials: Progress, persistent disparities, and emerging treatment dilemmas.

Progress in cardiovascular diseases·2026
See all related articles

Related Experiment Video

Updated: Jun 26, 2026

Isolation and Functional Characterization of Human Ventricular Cardiomyocytes from Fresh Surgical Samples
14:39

Isolation and Functional Characterization of Human Ventricular Cardiomyocytes from Fresh Surgical Samples

Published on: April 21, 2014

Ischemic cardiomyopathy.

G A Pantely, J D Bristow

    Progress in Cardiovascular Diseases
    |September 1, 1984
    PubMed
    Summary
    This summary is machine-generated.

    Ischemic cardiomyopathy, caused by coronary artery disease, presents variedly. Prognosis depends on heart dysfunction and disease extent, with therapy targeting ischemia and improving heart function.

    More Related Videos

    Isolation and Characterization of Cardiac Mesenchymal Stromal Cells from Endomyocardial Bioptic Samples of Arrhythmogenic Cardiomyopathy Patients
    09:16

    Isolation and Characterization of Cardiac Mesenchymal Stromal Cells from Endomyocardial Bioptic Samples of Arrhythmogenic Cardiomyopathy Patients

    Published on: February 28, 2018

    A Doxorubicin-Induced Murine Model of Dilated Cardiomyopathy In Vivo
    05:14

    A Doxorubicin-Induced Murine Model of Dilated Cardiomyopathy In Vivo

    Published on: May 16, 2020

    Related Experiment Videos

    Last Updated: Jun 26, 2026

    Isolation and Functional Characterization of Human Ventricular Cardiomyocytes from Fresh Surgical Samples
    14:39

    Isolation and Functional Characterization of Human Ventricular Cardiomyocytes from Fresh Surgical Samples

    Published on: April 21, 2014

    Isolation and Characterization of Cardiac Mesenchymal Stromal Cells from Endomyocardial Bioptic Samples of Arrhythmogenic Cardiomyopathy Patients
    09:16

    Isolation and Characterization of Cardiac Mesenchymal Stromal Cells from Endomyocardial Bioptic Samples of Arrhythmogenic Cardiomyopathy Patients

    Published on: February 28, 2018

    A Doxorubicin-Induced Murine Model of Dilated Cardiomyopathy In Vivo
    05:14

    A Doxorubicin-Induced Murine Model of Dilated Cardiomyopathy In Vivo

    Published on: May 16, 2020

    Area of Science:

    • Cardiology
    • Cardiovascular Medicine

    Background:

    • Ischemic cardiomyopathy (ICM) was initially defined as a syndrome indistinguishable from primary congestive cardiomyopathy, but caused by severe coronary artery disease.
    • The definition has broadened to encompass myocardial disease secondary to coronary artery disease.

    Purpose of the Study:

    • To discuss the varied clinical presentations of congestive and restrictive ischemic cardiomyopathy.
    • To explore how ischemia affects left ventricular systolic and diastolic performance, leading to diverse presentations.
    • To outline prognostic factors and therapeutic strategies for ischemic cardiomyopathy.

    Main Methods:

    • Review of clinical presentations of ischemic cardiomyopathy.
    • Analysis of the impact of ischemia on left ventricular function (systolic and diastolic).
    • Correlation of prognosis with ventricular dysfunction and coronary artery disease extent.

    Main Results:

    • Ischemic cardiomyopathy presents with varied clinical syndromes, including congestive and restrictive forms (stiff heart syndrome, right ventricular infarction).
    • Left ventricular systolic and diastolic dysfunction, driven by ischemia, underlies these varied presentations.
    • Prognosis is intrinsically linked to the severity of ventricular dysfunction and the extent of underlying coronary artery disease.

    Conclusions:

    • Therapeutic strategies for ischemic cardiomyopathy should focus on preventing or reducing myocardial ischemia.
    • Interventions aimed at halting or reversing myocardial function deterioration are crucial.
    • Effective management requires addressing both the ischemic cause and the resulting cardiac dysfunction.